BioPharmaPT
← All reports

Amgen Inc. — Lumykras EMA EPAR public assessment report (EMEA/H/C/005522, 2022)

Amgen Inc. · 2022 · EMA EPAR public assessment report · company profile →

Report summary

This report details the EMA's conditional marketing authorization for Lumykras (sotorasib) as a monotherapy for previously treated adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), addressing a significant unmet medical need. Clinical efficacy from the CodeBreaK 100 study showed an objective response rate of 37.4% and a median duration of response of 11.1 months. While generally well-tolerated, adverse events, including gastrointestinal issues and elevated liver enzymes, were observed. Non-clinical assessments indicated no genotoxicity or carcinogenicity. Sotorasib exhibits complex pharmacokinetics with low absorption and extensive CYP3A4 metabolism. A confirmatory Phase 3 trial (CodeBreaK 200) comparing sotorasib to docetaxel is ongoing. Some CHMP members expressed reservations regarding the sufficiency of efficacy data from the single-arm trial.

Key findings — cited to the page

Grade ≥3 GGT increased (NSCLC patients)2.6 % · p.133
Grade ≥3 Hepatotoxicity (NSCLC patients)15 % · p.139
Grade ≥3 hepatotoxicity adverse events (NSCLC patients)15 % · p.132
Grade ≥3 ALP increased (NSCLC patients)4.2 % · p.133
Grade ≥3 AEs (NSCLC patients)61 % · p.139
Grade ≥3 AEs (total any tumour type/any dose pool)53.3 % · p.139
Grade 5 TEAEs (NSCLC patients)35 cases · p.132
TEAE Grade ≥ 361 % · p.141
Grade ≥ 3 renal toxicity adverse events3 % · p.132
Hyponatremia (Grade ≥ 3 renal toxicity)2 % · p.132
Grade ≥3 Total bilirubin increased (NSCLC patients)1.6 % · p.133
AST increased (Grade ≥3) (NSCLC patients)6.5 % · p.139

Source: Amgen Inc. · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →

Amgen Inc. — Lumykras EMA EPAR public assessment report (EMEA/H/C/005522, 2022) — Summary & Key Findings | BioPharmaPT